InnovoTEX Due Diligence Call

InnovoTEX presented at WAA's 20-NovLife Sciences Pitch Event.

A due diligence call is on Tuesday, 03-Dec-2024 at 8am PT // 11am ET.

Please submit due diligence questions for InnovoTEX: InnovoTEX_DD_Pitch Follow-up Questions_20-Nov-2024

Joining information will be sent upon registration.

Develop multi-modal designer oncology drugs with improved efficacy and reduced toxicity using texaphyrin technology.

⭐ Sourced by Bill Kriebel

DEAL LEAD: Bill Kriebel ([email protected]) // @Bill Kriebel on Slack

• PROBLEM: Ovarian cancer is the leading cause of gynecological cancer mortality worldwide. Platinum-based drugs are widely used, however 80-90% of women diagnosed with advanced disease will develop platinum resistance. Clinical utility is limited by multiple resistance factors that prevent wt p53 activation by traditional cisplatin/carboplatin treatment.
• SOLUTION: InnovoTEX is developing an innovative drug discovery platform to identify and design targeted therapies that are well-tolerated, localize to solid tumors, and overcome platinum resistance targeting a unique mechanism known as ribosomal biosynthesis stress that induces wt-p53 activation and circumvents platinum resistance caused by DNA damage.
• Pitch Deck
• Pitch Presentation
• Deal Terms: 
  • Investment vehicle – seed preferred equity
  • Terms - $7.5M pre-money, $25K minimum, tiered warrant schedule
  • Max allocation – no maximum cap on investment
• Submit due diligence questions
• Dealum
• Slack: 1-innovotex